Aastrom to Host Fourth Quarter 2012 Investor Call on March 18, 2013

Tue Mar 12, 2013 4:15pm EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130312:nGNXUXIRAa

ANN ARBOR, Mich., March 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the
leading developer of patient-specific, expanded multicellular therapies for the treatment of
severe, chronic cardiovascular diseases, announces the following webcast:

 What:     Aastrom Biosciences, Inc., Fourth Quarter 2012 Investor Call                                                                                                                                     
 When:     Monday, March 18, 2013 at 4:30 pm (EDT)                                                                                                                                                          
 Where:    http://investors.aastrom.com/events.cfm http://www.globenewswire.com/newsroom/ctr?d=10024873&l=1&u=http%3A%2F%2Finvestors.aastrom.com%2Fevents.cfm                                               
 How:      -- The conference call will be available live in the Investors section of the Aastrom                                                                                                            
           website at http://investors.aastrom.com/events.cfm http://www.globenewswire.com/newsroom/ctr?d=10024873&l=1&u=http%3A%2F%2Finvestors.aastrom.com%2Fevents.cfm . Please access the site at least  
           15 minutes prior to the scheduled start time in order to download the required audio                                                                                                             
           software if necessary.                                                                                                                                                                           
                                                                                                                                                                                                            
           -- To participate in the live call by telephone, please call (877) 312-5881 and                                                                                                                  
           reference Aastrom Biosciences fourth quarter 2012 investor conference call. If calling                                                                                                           
           from outside the U.S., please use the international phone number (253) 237-1173.                                                                                                                 


If you are unable to participate during the live call, the webcast will be available at
http://investors.aastrom.com/events.cfm until March 18
http://www.globenewswire.com/newsroom/ctr?d=10024873&l=2&a=http%3A%2F%2Finvestors.aastrom.com%2Fevents.cfm%20until%20March%2018&u=http%3A%2F%2Finvestors.aastrom.com%2Fevents.cfm%2520until%2520March%252018
, 2014. A replay of the call will also be available until 11:59 pm (EDT) on March 22, 2013 by
calling (855) 859-2056, or from outside the U.S. at (404) 537-3406. The conference ID is 92135677.


About Aastrom Biosciences

Aastrom Biosciences is the leader in developing patient-specific, expanded multicellular therapies
for use in the treatment of patients with severe, chronic cardiovascular diseases. The company's
proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged
tissues. Aastrom has advanced ixmyelocel-T into late-stage clinical development, including a Phase
3 clinical program studying patients with critical limb ischemia and a Phase 2b clinical trial in
patients with ischemic dilated cardiomyopathy. For more information, please visit Aastrom's
website at www.aastrom.com
http://www.globenewswire.com/newsroom/ctr?d=10024873&l=4&a=www.aastrom.com&u=http%3A%2F%2Fwww.aastrom.com%2F
. For more information on the pivotal REVIVE Phase 3 clinical trial, please visit the trial
website at www.revivecli.com
http://www.globenewswire.com/newsroom/ctr?d=10024873&l=4&a=www.revivecli.com&u=http%3A%2F%2Fwww.revivecli.com%2F
.

The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
http://www.globenewswire.com/newsroom/ctr?d=10024873&l=5&u=http%3A%2F%2Fwww.globenewswire.com%2Fnewsroom%2Fprs%2F%3Fpkgid%3D3663


This document contains forward-looking statements, including, without limitation, statements
concerning clinical trial plans and progress, objectives and expectations, clinical activity
timing, intended product development, the performance and contribution of certain individuals and
expected timing of collecting and analyzing treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made through the use of words or
phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional verbs such as "will," "would,"
"should," "potential," "could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the forward-looking statements. Among the factors
that may result in differences are the inherent uncertainties associated with clinical trial and
product development activities, regulatory approval requirements, competitive developments, and
the availability of resources and the allocation of resources among different potential uses.
These and other significant factors are discussed in greater detail in Aastrom's Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange
Commission. These forward-looking statements reflect management's current views and Aastrom does
not undertake to update any of these forward-looking statements to reflect a change in its views
or events or circumstances that occur after the date of this release except as required by law.

CONTACT: Media contact
         Andrea Coan
         Berry & Company
         acoan@berrypr.com
         (212) 253-8881
         
         Investor contact
         Chad Rubin
         The Trout Group
         crubin@troutgroup.com
         (646) 378-2947

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.